Chronic Thromboembolic Pulmonary Hypertension Medical Management

Ryan Logue, Zeenat Safdar

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) is a common long-term complication of pulmonary embolism characterized by thromboembolic obstruction of the pulmonary arteries, vascular arteriopathy, vascular remodeling, and ultimately pulmonary hypertension (PH). Although pulmonary endarterectomy (PEA) surgery is the standard of care, approximately 40% of patients in the international CTEPH registry were deemed inoperable. In addition to lifelong anticoagulation, the cornerstone of PH-specific medical management is riociguat, a soluble guanylate cyclase stimulator. Medical management should be started early in CTEPH patients and may be used as a bridge to PEA surgery or balloon pulmonary angiography. Medical management is indicated for inoperable CTEPH patients and patients who have recurrence of PH after PEA surgery.

Original languageEnglish (US)
Pages (from-to)e29-e33
JournalMethodist DeBakey cardiovascular journal
Volume17
Issue number2
DOIs
StatePublished - 2021

Keywords

  • CTEPH
  • chronic thromboembolic pulmonary hypertension
  • pulmonary embolism
  • pulmonary endarterectomy
  • riociguat

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Chronic Thromboembolic Pulmonary Hypertension Medical Management'. Together they form a unique fingerprint.

Cite this